Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 9/20 | 0.53 |
| ▸ | DRD3 | P35462 | 7/20 | 0.53 |
| ▸ | DRD2 | P14416 | 6/20 | 0.53 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 5/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 4/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291697 | 0.83 | TACR1 (0.74) | TACR1DRD4DRD3DRD2LTA4H | |
| SCHEMBL7826925 | 0.83 | TACR1 (0.74) | TACR1DRD4DRD3DRD2LTA4H | |
| SCHEMBL27334561 | 0.83 | TACR1 (0.74) | TACR1DRD4DRD3DRD2LTA4H | |
| SCHEMBL8858021 | 0.79 | DRD4 (0.77) | DRD4DRD3DRD2METHTR2A | |
| SCHEMBL4283381 | 0.77 | LTA4H (0.55) | TACR1LTA4HCYP3A4CYP2D6SIGMAR1 | |
| SCHEMBL4290226 | 0.77 | LTA4H (0.52) | LTA4HSIGMAR1MAPK1 | |
| SCHEMBL878847 | 0.77 | BCHE (0.59) | DRD4DRD3DRD2METOPRM1 | |
| SCHEMBL7470933 | 0.76 | LTA4H (0.51) | TACR1DRD4LTA4HCYP2D6TSHR | |
| SCHEMBL18325 | 0.76 | LTA4H (0.61) | TACR1LTA4HCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24350 | 0.76 | LTA4H (0.61) | TACR1LTA4HCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094779-B2 | Piperazine oxime dervatives having NK-1 receptor antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-08-22 | — | — | US | disclosed |
| EP-1406894-B1 | PIPERAZINE OXIME DERIVATIVES HAVING NK-1 RECEPTOR ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2004-12-22 | — | — | EP | disclosed |
| US-20040176389-A1 | Piperazine oxime dervatives having nk-1 receptor antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-09-09 | — | — | US | disclosed |
| EP-1406894-A1 | PIPERAZINE OXIME DERIVATIVES HAVING NK-1 RECEPTOR ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003006459-A1 | PIPERAZINE OXIME DERIVATIVES HAVING NK-1 RECEPTOR ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176389-A1 | Piperazine oxime dervatives having nk-1 receptor antagonistic activity | TACR2, OPRK1, TACR1 | TACR1 3/4885DRD4 289/4885DRD3 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.